Prognostic gene alterations and clonal changes in childhood B-ALL.


Journal

Leukemia research
ISSN: 1873-5835
Titre abrégé: Leuk Res
Pays: England
ID NLM: 7706787

Informations de publication

Date de publication:
08 2019
Historique:
received: 11 03 2019
revised: 17 05 2019
accepted: 22 05 2019
pubmed: 23 6 2019
medline: 21 5 2020
entrez: 23 6 2019
Statut: ppublish

Résumé

Genomic profiles of leukemia patients lead to characterization of variations that provide the molecular classification of risk groups, prediction of clinical outcome and therapeutic decisions. In this study, we examined the diagnostic (n = 77) and relapsed (n = 31) pediatric B-cell acute lymphoblastic leukemia (B-ALL) samples for the most common leukemia-associated gene variations CRLF2, JAK2, PAX5 and IL7R using deep sequencing and copy number alterations (CNAs) (CDKN2A/2B, PAX5, RB1, BTG1, ETV6, CSF2RA, IL3RA and CRLF2) by multiplex ligation proximity assay (MLPA), and evaluated for the clonal changes through relapse. Single nucleotide variations SNVs were detected in 19% of diagnostic 15.3% of relapse samples. The CNAs were detected in 55% of diagnosed patients; most common affected genes were CDKN2A/2B, PAX5, and CRLF2. Relapse samples did not accumulate a greater number of CNAs or SNVs than the cohort of diagnostic samples, but the clonal dynamics showed the accumulation/disappearance of specific gene variations explained the course of relapse. The CDKN2A/2B were most frequently altered in relapse samples and 32% of relapse samples carried at least one CNA. Moreover, CDKN2A/2B alterations and/or JAK2 variations were associated with decreased relapse-free survival. On the other hand, CRLF2 copy number alterations predicted a better survival rate in B-ALL. These findings contribute to the knowledge of CDKN2A/2B and CRLF2 alterations and their prognostic value in B-ALL. The integration of genomic data in clinical practice will enable better stratification of ALL patients and allow deeper understanding of the nature of relapse.

Identifiants

pubmed: 31228652
pii: S0145-2126(19)30097-9
doi: 10.1016/j.leukres.2019.05.009
pii:
doi:

Substances chimiques

Neoplasm Proteins 0

Types de publication

Clinical Trial Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

106159

Informations de copyright

Copyright © 2019 Elsevier Ltd. All rights reserved.

Auteurs

Yucel Erbilgin (Y)

Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Sinem Firtina (S)

Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; Istinye University, Faculty of Arts and Sciences, Istanbul, Turkey.

Sevcan Mercan (S)

Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; Kafkas University, Faculty of Engineering, Kars, Turkey.

Ozden Hatirnaz Ng (O)

Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; Acibadem Mehmet Ali Aydinlar University Medical Faculty, Istanbul, Turkey.

Serap Karaman (S)

Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey.

Orcun Tasar (O)

Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Zeynep Karakas (Z)

Istanbul University, Aziz Sancar Institute of Experimental Medicine, Istanbul, Turkey.

Tulin Tiraje Celkan (TT)

Istanbul Cerrahpasa University Medical Faculty, Istanbul, Turkey.

Emine Zengin (E)

Kocaeli University Medical Faculty, Kocaeli, Turkey.

Nazan Sarper (N)

Kocaeli University Medical Faculty, Kocaeli, Turkey.

Zeynep Yildiz Yildirmak (ZY)

Istanbul Sisli Hamidiye Etfal Education and Research Hospital, Istanbul, Turkey.

Sinem Sisko (S)

Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey.

Ugur Ozbek (U)

Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey; Acibadem Mehmet Ali Aydinlar University Medical Faculty, Istanbul, Turkey.

Muge Sayitoglu (M)

Aziz Sancar Institute of Experimental Medicine, Istanbul University, Istanbul, Turkey. Electronic address: mugeay@istanbul.edu.tr.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH